Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Netivudine 是一种有效的核苷类逆转录酶抑制剂(NRTIs),是一种核苷类似物,具有抗水痘带状疱疹病毒活性,可用于治疗人类免疫缺陷病毒(HIV)感染。Netivudine 通过抑制逆转录酶起作用,通过抑制作用减少体内的病毒载量,减缓疾病的进展。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,780 | 现货 | ||
5 mg | ¥ 4,480 | 现货 | ||
10 mg | ¥ 6,380 | 现货 | ||
25 mg | ¥ 9,620 | 现货 | ||
50 mg | ¥ 12,900 | 现货 | ||
100 mg | ¥ 17,500 | 现货 | ||
500 mg | ¥ 34,800 | 现货 |
产品描述 | Netivudine is a potent nucleoside reverse transcriptase inhibitor (NRTIs), a nucleoside analogue with anti-varicella zoster virus activity that can be used to treat human immunodeficiency virus (HIV) infection. Netivudine works by inhibiting reverse transcriptase, which reduces viral load in the body and slows the progression of the disease through its inhibitory effect. |
靶点活性 | VZV:0.6-3.8μM |
体外活性 | The phosphorylation of netivudine in VZV infected human cells is similar to that of sorivudine and the IC50 of netivudine for VZV ranges from 06-3.8 uM. Since, in HSV-infected cells, only the monophosphate is formed, netivudine shows no appreciable in vitro activity against HSV or other human herpesviruses.[1] |
体内活性 | The half-life of netivudine in humans is about 12-15 hand preliminary pharmacokinetic studies, employing oral doses of netivudine at 100 mg, 200 mg and 400 mg in young adults and healthy elderly volunteers, confirmed that concentrations of the drug substantially above the IC50 for VZV could be achieved and sustained with twice daily dosing.[2] The drug bioavailability was 21.1% and 24.6% in the young and elderly, respectively. An initial, open, dose-ranging study of netivudine in 31 elderly immunocompetent patients with localised herpes zoster with oral doses up to 200mg twice daily showed therapeutic benefits upon rash healing and pain and no significant adverse effects.[3] |
分子量 | 282.25 |
分子式 | C12H14N2O6 |
CAS No. | 84558-93-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (194.86 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.543 mL | 17.7148 mL | 35.4296 mL | 88.574 mL |
5 mM | 0.7086 mL | 3.543 mL | 7.0859 mL | 17.7148 mL | |
10 mM | 0.3543 mL | 1.7715 mL | 3.543 mL | 8.8574 mL | |
20 mM | 0.1771 mL | 0.8857 mL | 1.7715 mL | 4.4287 mL | |
50 mM | 0.0709 mL | 0.3543 mL | 0.7086 mL | 1.7715 mL | |
100 mM | 0.0354 mL | 0.1771 mL | 0.3543 mL | 0.8857 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Netivudine 84558-93-0 Inhibitor inhibitor inhibit